A multivalent subunit vaccine augments pre-existing immunity to protect against T3SS-positive Pseudomonas aeruginosa but reveals immunological interference against ExlA-positive strains
Aug 2026· Infection and Immunity· Vol 94· 0 citations· 31 references
Medicine
TL;DR
It is established that the vaccine formulation can effectively boost and redirect pre-existing immunity, offering a promising approach to overcome the limitations of natural exposure and protect at-risk individuals from diverse Pa infections.
Abstract
ABSTRACT Pseudomonas aeruginosa (Pa) is a ubiquitous, opportunistic nosocomial pathogen that poses a significant threat due to its innate and acquired multidrug resistance. Novel vaccine strategies are urgently needed for vulnerable populations, many of which harbor pre-existing immunity from prior encounters with Pa. Here, we evaluated a multivalent subunit vaccine combining type III secretion system (T3SS) antigens and exolysin A (ExlA) in a nanoemulsion formulation using a clinically relevant murine pulmonary pre-exposure model. This approach allowed us to determine whether vaccination could overcome the limitations of the host’s initial, ineffective immune response. Vaccination fundamentally transforms suboptimal baseline memory into a potent, multi-faceted Th1/Th17-polarized response. This globally transformed signature was characterized by significantly enhanced antigen-specific IFN-γ and IL-17A production, both locally and systematically in the lung, with exceptionally large biological effect sizes (Cohen’s d values reaching 21.35). By utilizing log10 transformation to accurately reflect pathogen growth kinetics, we demonstrated that this vaccine-augmented immunity conferred statistically significant protection following heterologous challenge. In the twice-exposed cohort, vaccination promoted superior bacterial clearance of the T3SS-positive strain, though clearance of the ExlA-positive strain was not enhanced, potentially due to immunological interference from pre-existing T3SS memory. In the thrice-exposed cohort, a functional protective threshold was observed, where high levels of natural immunity matched the vaccine-induced clearance levels. Our findings established that our vaccine formulation can effectively boost and redirect pre-existing immunity, offering a promising approach to overcome the limitations of natural exposure and protect at-risk individuals from diverse Pa infections.
The identification of a multi-antigen vaccine candidate, Ad-8CPR2, as the most immunogenic construct, which incorporates M. tuberculosis antigenic proteins with strong immunogenicity and functional properties, which are fused with peptide segments capable of augmenting antigen-specific immune responses.
Li-Qun Wei, Peng Wang, Ying Li et al.· Microbiology spectrum· 0 citations
These findings revealed that incorporating HKCC significantly increased cellular responses and mucosal IgA and systemic IgG titres in pre- and post-exposure models, respectively, and correlated with reduced mycobacterial burden in the lungs, spleens, and livers and with improved lung pathology.
Shanika Werellagama, Nancy Gupta, Jie Li et al.· Emerging Microbes and Infect...· 0 citations
It is shown that protective immunity conferred by mucosal mRNA vaccines (but not parenteral) require neither serum IgG nor airway secretory IgA, but instead depends on a previously unrecognized lung-resident CD8⁺IL-17⁺ T-cells (Tc17) that rapidly recruits neutrophils/macrophages to eliminate bacteria.
The preclinical development of a novel HCV vaccine candidate engineered by formulating a novel native-like secreted E1E2 immunogen and a well-established combinatorial adjuvant of QS-21 + 3D-(6-acyl) PHAD into unique microneedle patches (MNPs).
Yi-Nuo Zhang, A. Dhayani, Stephen C. Balmert et al.· Journal of Immunology· 0 citations
It is shown that a conjugated, dual TLR2/7 agonist CL413 and NP antigen can enhance both antibody and T cell responses after intramuscular injection and provide enhanced heterosubtypic immunity to lethal IAV infection compared to either agonist alone.
Deborah M Brown, Maria Crespo Friere, Alinur Jaboldinov et al.· Journal of Immunology· 0 citations